An IGF-1R antagonist
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

JB-1 (trifluoroacetate salt)

Item No. 44046

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-cysteinyl-L-tyrosyl-L-alanyl-L-alanyl-L-prolyl-L-leucyl-L-lysyl-L-prolyl-L-alanyl-L-lysyl-L-seryl-L-cysteine, cyclic (1→12)-disulfide, trifluoroacetate salt
Synonyms
  • Cyclic [CYAAPLKPAKSC]
  • cyclo(CYAAPLKPAKSC)
  • IGF-1 Analog
Molecular Formula
C55H88N14O15S2 • XCF3COOH
Formula Weight
1249.5
Purity
≥95%
Formulation (Request formulation change)
A crystalline solid
Peptide Sequence
c(CYAAPLKPAKSC)
Solubility(Learn about Variance in Solubility)
Water: Slightly soluble: 0.1-1 mg/ml
SMILES
O=C([C@@H](NC([C@@H](NC([C@@]1([H])N(C([C@@H](NC([C@@H](NC([C@@H](NC2=O)CC(C=C3)=CC=C3O)=O)C)=O)C)=O)CCC1)=O)CC(C)C)=O)CCCCN)N4[C@@](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CSSC[C@@H]2N)C(O)=O)=O)CO)=O)CCCCN)=O)C)=O)([H])CCC4.OC(C(F)(F)F)=O
InChi Code
InChI=1S/C55H88N14O15S2.C2HF3O2/c1-29(2)24-38-49(77)63-37(13-7-9-21-57)54(82)69-23-11-14-42(69)51(79)60-31(4)45(73)62-36(12-6-8-20-56)47(75)66-40(26-70)50(78)67-41(55(83)84)28-86-85-27-35(58)46(74)64-39(25-33-16-18-34(71)19-17-33)48(76)59-30(3)44(72)61-32(5)53(81)68-22-10-15-43(68)52(80)65-38;3-2(4,5)1(6)7/h16-19,29-32,35-43,70-71H,6-15,20-28,56-58H2,1-5H3,(H,59,76)(H,60,79)(H,61,72)(H,62,73)(H,63,77)(H,64,74)(H,65,80)(H,66,75)(H,67,78)(H,83,84);(H,6,7)/t30-,31-,32-,35-,36-,37-,38-,39-,40-,41-,42-,43-;/m0./s1
InChi Key
IWFHEUONBROAAH-XOQGUAMSSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $54

    Add

    5 mg

    $229

    Add

    10 mg

    $351

    Add
    Kinase Resource Center
    Discover Products & Resources for Kinase Research
    • Kinase inhibitors, screening libraries, assay kits, & more
    • Tools to study kinase signaling pathways:
      • Growth factor signaling
      • PI3K/Akt/mTOR
      • MAPKs (ERK, p38, & JNK)
      • JAK/STAT signaling
    • Articles, resources, & advice
    EXPLORE NOW
    Product Description

    JB-1 is an insulin-like growth factor 1 receptor (IGF-1R) antagonist and a cyclic derivative of IGF-1 (60-70).1 It inhibits IGF-1-induced IGF-1R autophosphorylation and proliferation in BALB/c 3T3 cells overexpressing IGF-1R when used at a concentration of 1 µg/ml. Intracerebroventricular administration of JB-1 (4 µg/animal) reduces estradiol- and progesterone-induced increases in serum luteinizing hormone (LH) levels in ovariohysterectomized rats.2 It also decreases lordosis behavior in the same rats. JB-1 inhibits oxygen-induced decreases in body weight and increases in retinal vascular overgrowth in a neonatal rat model of oxygen-induced retinopathy.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Pietrzkowski, Z., Wernicke, D., Porcu, P., et al. Inhibition of cellular proliferation by peptide analogues of insulin-like growth factor 1. Cancer Res. 52(23), 6447-6451 (1992).

    2. Quesada, A., and Etgen, A.M. Functional interactions between estrogen and insulin-like growth factor-I in the regulation of α1B-adrenoceptors and female reproductive function. J. Neurosci. 22(6), 2401-2408 (2002).

    3. Brock, R.S., Gebrekristos, B.H., Kuniyoshi, K.M., et al. Biomolecular effects of Jb1 (an IGF-I peptide analog) in a rat model of oxygen-induced retinopathy. Pediatr. Res. 69(2), 135-141 (2011).